Patents by Inventor Dieter Seidelmann

Dieter Seidelmann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Aza- and polyazanthranyl amides and their use as medicaments
    Publication number: 20110071165
    Abstract: Aza- and polyazanthranyl amides and their use as medicaments in the treatment of diseases caused by persistent angiogenesis are described, as well as the intermediates used in the preparation of the aza- and polyazanthranyl amides.
    Type: Application
    Filed: November 24, 2010
    Publication date: March 24, 2011
    Applicant: NOVARTIS AG
    Inventors: Dieter SEIDELMANN, Martin KRÜGER, Orlin PETROV, Andreas HUTH, Karl-Heinz THIERAUCH, Andreas MENRAD, Martin HABEREY
  • Substituted Benzoic Acid Amides and Use thereof for the Inhibition of Angiogenesis
    Publication number: 20110009447
    Abstract: Substituted benzoic acid amides of formula (I) and their use as pharmaceutical agents for treating diseases that are triggered by persistent angiogenesis as well as their intermediate products for the production of benzoic acid amides are described.
    Type: Application
    Filed: April 24, 2001
    Publication date: January 13, 2011
    Inventors: Andreas Huth, Dieter Seidelmann, Karl-Heinz Thierauch
  • Azanthranylalkyl and -cycloalkyl amides and their use as VEGF receptor inhibitors
    Patent number: 7479491
    Abstract: The invention relates to substituted anthranylalkyl and -cycloalkyl amides of general formula (I) and to their use as medicaments for treating diseases caused by persistent angiogenesis.
    Type: Grant
    Filed: September 21, 2004
    Date of Patent: January 20, 2009
    Assignee: Novartis AG
    Inventors: Dieter Seidelmann, Martin Krueger, Eckhard Ottow, Andreas Huth, Karl-Heinz Thierauch, Andreas Menrad, Martin Haberey
  • Aza- and polyazanthranyl amides and their use as medicaments
    Publication number: 20060287339
    Abstract: Aza- and polyazanthranyl amides and their use as medicaments in the treatment of diseases caused by persistent angiogenesis are described, as well as the intermediates used in the preparation of the aza- and polyazanthranyl amides.
    Type: Application
    Filed: August 25, 2006
    Publication date: December 21, 2006
    Inventors: Dieter Seidelmann, Martin Kruger, Orlin Petrov, Andreas Huth, Karl-Heinz Thierauch, Andreas Menrad, Martin Haberey
  • Anthranilic acid amides and the use thereof as medicaments
    Patent number: 7122547
    Abstract: The invention relates to anthranilic acid amides and the use thereof as medicaments for the treatment of diseases that are triggered by persistent angiogenesis, in addition to intermediate products in the production of anthranilic acid amides.
    Type: Grant
    Filed: November 9, 1999
    Date of Patent: October 17, 2006
    Assignees: Schering AG, Novartis AG
    Inventors: Andreas Huth, Dieter Seidelmann, Karl-Heinz Thierauch, Guido Bold, Paul William Manley, Pascal Furet, Jeanette Marjorie Wood, Jürgen Mestan, Jose Brüggen, Stefano Ferrari, Martin Krüger, Eckhard Ottow, Andreas Menrad, Michael Schirner
  • Ortho-substituted anthranilic acid amides and their use as medicaments
    Patent number: 7081468
    Abstract: Ortho-substituted anthranilic acid amides and use thereof as pharmaceutical agents for treating diseases that are triggered by persistent angiogenesis are described.
    Type: Grant
    Filed: May 8, 2001
    Date of Patent: July 25, 2006
    Assignee: Schering AG
    Inventors: Martin Krueger, Andreas Huth, Orlin Petrov, Dieter Seidelmann, Karl-Heinz Thierauch, Martin Haberey, Andreas Menrad, Alexander Ernst
  • N-aryl (thio) anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors
    Publication number: 20060074112
    Abstract: Described are compunds of formula (I), wherein W is O or S; X is NR8; Y is CR9R10—(CH2)n wherein R9 and R10 are independently of each other hydrogen or lower alkyl, and n is an integer of from and including 0 to and including 3; or Y is SO2; R1 is aryl; R2 is a mono- or bicyclic heteroaryl group comprising one or more ring nitrogen atoms with the exception that R2 cannot represent 2-phthalimidyl, and in case of Y?SO2 cannot represent 2,1,3-benzothiadiazol-4-yl; any of R3, R4, R5 and R6, independently of the other, is H or a substituent other than hydrogen; and R7 and R8, independently of each, other, are H or lower alkyl; or a N-oxide or a pharmaceutically acceptable salt thereof for the preparation of a pharmaceutical product for the treatment of a neoplastic disease which responds to an inhibition of the VEGF receptor tyrosine kinase activity. The compounds of formula (I) can be used for the treatment e.g. of a neoplastic disease, such as a tumor disease, of retinopathy and age-related macular degeneration.
    Type: Application
    Filed: October 20, 2005
    Publication date: April 6, 2006
    Inventors: Karl-Heinz Altmann, Guido Bold, Pascal Furet, Paul Manley, Jeanette Wood, Stefano Ferrari, Francesco Hofmann, Jurgen Mestan, Andreas Huth, Martin Kruger, Dieter Seidelmann, Andreas Menrad, Martin Haberey, Karl-Heinz Thierauch
  • Anthranyl amides and their use as medicaments
    Patent number: 7012081
    Abstract: Substituted anthranilamides and use thereof as pharmaceutical agents for treating diseases that are triggered by persistent angiogenesis as well as their intermediate products for the production of anthranilamides are described.
    Type: Grant
    Filed: May 7, 2001
    Date of Patent: March 14, 2006
    Assignee: Schering AG
    Inventors: Martin Krueger, Andreas Huth, Orlin Petrov, Dieter Seidelmann, Karl-Heinz Thierauch, Martin Haberey, Andreas Menrad, Alexander Ernst
  • N-Aryl (thio) anthranilic acid amide derivatives, their preparation and their use as VEGF
    Patent number: 7002022
    Abstract: Described are compunds of formula (I), wherein W is O or S; X is NR8; Y is CR9R10—(CH2)n wherein R9 and R10 are independently of each other hydrogen or lower alkyl, and n is an integer of from and including 0 to and including 3; or Y is SO2; R2 is aryl; R2 is a mono- or bicyclic heteroaryl group comprising one or more ring nitrogen atoms with the exception that R2 cannot represent 2-phthalimidyl, and in case of Y=SO2 cannot represent 2,1,3-benzothiadiazol-4-yl; any of R3, R4, R5 and R6, independently of the other, is H or a substituent other than hydrogen; and R7 and R8, independently of each other, are H or lower alkyl; or a N-oxide or a pharmaceutically acceptable salt thereof for the preparation of a pharmaceutical product for the treatment of a neoplastic disease which responds to an inhibition of the VEGF receptor tyrosine kinase activity. The compounds of formula (I) can be used for the treatment e.g. of a neoplastic disease, such as a tumor disease, of retinopathy and age-related macular degeneration.
    Type: Grant
    Filed: April 21, 2004
    Date of Patent: February 21, 2006
    Assignees: Novartis AG, Schering Aktiengesellschaft
    Inventors: Karl-Heinz Altmann, Guido Bold, Pascal Furet, Paul William Manley, Jeanette Marjorie Wood, Stefano Ferrari, Francesco Hofmann, Jürgen Mestan, Andreas Huth, Martin Krüger, Dieter Seidelmann, Andreas Menrad, Martin Haberey, Karl-Heinz Thierauch
  • Ortho-substituted anthranilic acid amides and their use as pharmaceutical agents
    Publication number: 20060014747
    Abstract: Ortho-substituted anthranilic acid amides and use thereof as pharmaceutical agents for treating diseases that are triggered by persistent angiogenesis are described.
    Type: Application
    Filed: September 6, 2005
    Publication date: January 19, 2006
    Inventors: Martin Krueger, Andreas Huth, Orlin Petrov, Dieter Seidelmann, Karl-Heinz Thierauch, Martin Haberey, Andreas Menrad, Alexander Ernst
  • Anthranilamides and their use as pharmaceutical agents
    Publication number: 20050261343
    Abstract: Substituted anthranilamides and use thereof as pharmaceutical agents for treating diseases that are triggered by persistent angiogenesis as well as their intermediate products for the production of anthranilamides are described.
    Type: Application
    Filed: August 1, 2005
    Publication date: November 24, 2005
    Inventors: Martin Krueger, Andreas Huth, Orlin Petrov, Dieter Seidelmann, Karl-Heinz Thierauch, Martin Haberey, Andreas Menrad, Alexander Ernst
  • VEGF receptor tyrosine kinase inhibitors
    Patent number: 6878720
    Abstract: Described are compunds of formula (I), wherein W is O or S; X is NR8; Y is CR9R10—(CH2)n wherein R9 and R10 are independently of each other hydrogen or lower alkyl, and n is an integer of from and including 0 to and including 3; or Y is SO2; R1 is aryl; R2 is a bicyclic heteroaryl group comprising one ring nitrogen atom with the exception that R2 cannot represent 2-phthalimidyl; any of R3, R4, R5 and R6, independently of the other, is H or a substituent other than hydrogen; and R7 and R8, independently of each other, are H or lower alkyl; or a N-oxide or a pharmaceutically acceptable salt thereof for the preparation of a pharmaceutical product for the treatment of a neoplastic disease which responds to an inhibition of the VEGF receptor tyrosine kinase activity. The compounds of formula (I) can be used for the treatment e.g. of a neoplastic disease, such as a tumor disease, of retinopathy and age-related macular degeneration.
    Type: Grant
    Filed: June 26, 2002
    Date of Patent: April 12, 2005
    Assignees: Novartis AG, Schering Aktiengesellschaft
    Inventors: Karl-Heinz Altmann, Guido Bold, Pascal Furet, Paul William Manley, Jeanette Marjorie Wood, Stefano Ferrari, Francesco Hofmann, Jürgen Mestan, Andreas Huth, Martin Krüger, Dieter Seidelmann, Andreas Menrad, Martin Haberey, Karl-Heinz Thierauch
  • Azanthranylalkyl and -cycloalkyl amides and their use as VEGF receptor inhibitors
    Publication number: 20050054692
    Abstract: The invention relates to substituted anthranylalkyl and -cycloalkyl amides of general formula (I) and to their use as medicaments for treating diseases caused by persistent angiogenesis.
    Type: Application
    Filed: September 21, 2004
    Publication date: March 10, 2005
    Inventors: Dieter Seidelmann, Martin Kruger, Eckhard Ottow, Andreas Huth, Karl-Heinz Thierauch, Andreas Menrad, Martin Haberey
  • Anthranylalkyl and cycloalkyl amides and use thereof as VEGF receptor inhibitors
    Patent number: 6818661
    Abstract: The invention relates to substituted anthranylalkyl and cycloalkyl amides of general formula (I) and to their use as medicaments for treating diseases caused by persistent angiogenesis.
    Type: Grant
    Filed: May 9, 2003
    Date of Patent: November 16, 2004
    Assignee: Novartis AG
    Inventors: Dieter Seidelmann, Martin Krüger, Eckhard Ottow, Andreas Huth, Karl-Heinz Thierauch, Andreas Menrad, Martin Haberey
  • Aza-and polyazanthranyl amides and their use as medicaments
    Publication number: 20040224968
    Abstract: The invention relates to aza- and polyazanthranyl amides, to their use as medicaments for treating diseases caused by persistent angiogenesis and to their intermediate products for producing the aza- and polyazanthranyl amides.
    Type: Application
    Filed: May 9, 2003
    Publication date: November 11, 2004
    Inventors: Dieter Seidelmann, Martin Krger, Orlin Petrov, Andreas Huth, Karl-Heinz Thierauch, Andreas Menrad, Martin Haberey
  • N-aryl (THIO) anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors
    Publication number: 20040198782
    Abstract: 1
    Type: Application
    Filed: April 21, 2004
    Publication date: October 7, 2004
    Inventors: Karl-Heinz Altmann, Guido Bold, Pascal Furet, Paul William Manley, Jeanette Marjorie Wood, Stefano Ferrari, Francesco Hofmann, Jurgen Mestan, Andreas Huth, Martin Kruger, Dieter Seidelmann, Andreas Menrad, Martin Haberey, Karl-Heinz Thierauch
  • Ortho-substituted anthranilic acid amides and their use as medicaments
    Publication number: 20040102441
    Abstract: Ortho-substituted anthranilic acid amides and use thereof as pharmaceutical agents for treating diseases that are triggered by persistent angiogenesis are described.
    Type: Application
    Filed: June 24, 2003
    Publication date: May 27, 2004
    Inventors: Martin Krueger, Andreas Huth, Orlin Petrov, Dieter Seidelmann, Karl-Heinz Thierauch, Martin Haberey, Andreas Menrad, Alexander Ernst
  • Anthranyl amides and their use as medicaments
    Publication number: 20040029880
    Abstract: Substituted anthranilamides and use thereof as pharmaceutical agents for treating diseases that are triggered by persistent angiogenesis as well as their intermediate products for the production of anthranilamides are described.
    Type: Application
    Filed: June 23, 2003
    Publication date: February 12, 2004
    Inventors: Martin Krueger, Andreas Huth, Orlin Petrov, Dieter Seidelmann, Karl-Heinz Thierauch, Martin Haberey, Andreas Menrad, Alexander Ernst
  • Anthranylalkyl and cycloalkyl amides and use thereof as vegf receptor inhibitors
    Publication number: 20030176469
    Abstract: The invention relates to substituted anthranylalkyl and cycloalkyl amides of general formula (I) and to their use as medicaments for treating diseases caused by persistent angiogenesis.
    Type: Application
    Filed: May 9, 2003
    Publication date: September 18, 2003
    Inventors: Dieter Seidelmann, Martin Kruger, Eckhard Ottow, Andreas Huth, Karl-heinz Thierauch, Andreas Menrad, Martin Haberey
  • N-aryl (thio) anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors
    Publication number: 20030064992
    Abstract: 1
    Type: Application
    Filed: June 26, 2002
    Publication date: April 3, 2003
    Inventors: Karl-Heinz Altmann, Guido Bold, Pascal Furet, Paul William Manley, Jeanette Marjorie Wood, Stefano Ferrari, Francesco Hofmann, Jurgen Mestan, Andreas Huth, Martin Kruger, Dieter Seidelmann, Andreas Menrad, Martin Haberey, Karl-Heinz Thierauch